Remarkably, this independent dataset revealed a significant, progressive downregulation of ANXA1 from distal normal tissues, through premalignant lesions, primary tumors, lymph node metastases, to recurrent/metastatic tumors (Fig. 5B). Here, ANXA1 is linked to metastatic neoplasm.